Police & Firemen s Retirement System of New Jersey Grows Stake in Spyre Therapeutics, Inc. $SYRE

Police & Firemen s Retirement System of New Jersey increased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 31.5% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,525 shares of the company’s stock after buying an additional 2,758 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Spyre Therapeutics were worth $173,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in shares of Spyre Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,227,232 shares of the company’s stock valued at $18,373,000 after acquiring an additional 167,669 shares during the last quarter. ProShare Advisors LLC lifted its position in Spyre Therapeutics by 9.7% during the second quarter. ProShare Advisors LLC now owns 12,479 shares of the company’s stock valued at $187,000 after purchasing an additional 1,101 shares during the last quarter. Emerald Advisers LLC increased its holdings in shares of Spyre Therapeutics by 3.3% in the 2nd quarter. Emerald Advisers LLC now owns 565,863 shares of the company’s stock worth $8,471,000 after buying an additional 18,036 shares during the last quarter. AlphaQuest LLC raised its position in shares of Spyre Therapeutics by 30.8% during the 2nd quarter. AlphaQuest LLC now owns 4,174 shares of the company’s stock valued at $62,000 after buying an additional 983 shares in the last quarter. Finally, TD Asset Management Inc lifted its holdings in shares of Spyre Therapeutics by 409.5% during the 2nd quarter. TD Asset Management Inc now owns 113,968 shares of the company’s stock worth $1,706,000 after acquiring an additional 91,600 shares during the last quarter. 80.39% of the stock is currently owned by institutional investors.

Spyre Therapeutics Stock Up 1.0%

Shares of SYRE stock opened at $30.05 on Friday. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -8.84 and a beta of 2.99. The stock has a fifty day moving average of $21.83 and a 200 day moving average of $18.09. Spyre Therapeutics, Inc. has a 52 week low of $10.91 and a 52 week high of $30.21.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.53. Equities research analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SYRE. Wedbush restated an “outperform” rating and set a $65.00 price target on shares of Spyre Therapeutics in a research report on Wednesday, August 6th. Deutsche Bank Aktiengesellschaft initiated coverage on Spyre Therapeutics in a research report on Friday, September 26th. They issued a “buy” rating and a $43.00 target price for the company. Wall Street Zen upgraded shares of Spyre Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. BTIG Research reissued a “buy” rating and set a $70.00 price target on shares of Spyre Therapeutics in a research note on Tuesday, September 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Spyre Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $50.00.

Insider Activity

In other Spyre Therapeutics news, CFO Scott L. Burrows sold 18,428 shares of Spyre Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $16.26, for a total transaction of $299,639.28. Following the sale, the chief financial officer directly owned 97,994 shares of the company’s stock, valued at approximately $1,593,382.44. The trade was a 15.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Cameron Turtle sold 45,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $23.33, for a total value of $1,049,850.00. Following the transaction, the chief executive officer owned 701,907 shares in the company, valued at $16,375,490.31. This trade represents a 6.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 15.43% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).